Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan
To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient population. In a post-marketing observational co...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | eNeurologicalSci |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405650221000678 |
| _version_ | 1819009528134369280 |
|---|---|
| author | Ryuji Kaji Akira Endo Michiko Sugawara Mika Ishii |
| author_facet | Ryuji Kaji Akira Endo Michiko Sugawara Mika Ishii |
| author_sort | Ryuji Kaji |
| collection | DOAJ |
| description | To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient population. In a post-marketing observational cohort study, 150 patients previously treated with botulinum toxin type A were enrolled, of whom 138 were followed up for 1 year after the initial type B injection. Final observation data were available for 122 patients. Efficacy was evaluated using the Toronto Western Spasmodic Torticollis Rating Scale. Total score improved from 39.9 at baseline to 34.3 at 4 weeks after the first injection, and pain score improved from 8.9 to 7.9. Improvements were maintained through six further injections in two subpopulations: patients who showed resistance to botulinum toxin type A and patients who were not type A resistant but switched to type B. For a number of patients, even low doses (<5000 units) of botulinum toxin type B demonstrated efficacy. These findings support the efficacy of botulinum toxin type B in clinical settings for the management of CD symptoms, including pain, even at low doses, regardless of the patient's botulinum toxin type A resistance status. |
| first_indexed | 2024-12-21T00:57:48Z |
| format | Article |
| id | doaj.art-160c2045227b4c5fb2abdf6b88488561 |
| institution | Directory Open Access Journal |
| issn | 2405-6502 |
| language | English |
| last_indexed | 2024-12-21T00:57:48Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | eNeurologicalSci |
| spelling | doaj.art-160c2045227b4c5fb2abdf6b884885612022-12-21T19:21:15ZengElseviereNeurologicalSci2405-65022021-12-0125100374Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in JapanRyuji Kaji0Akira Endo1Michiko Sugawara2Mika Ishii3National Hospital Organization Utano National Hospital, 8 Narutaki Ondoyama-cho, Ukyo-ku, Kyoto, Japan; Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramotocho, Tokushima, JapanClinical Planning and Development, Medical HQs, Eisai Co., Ltd., 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan; Corresponding author.Scientific Intelligence Group, Medical HQs, Eisai Co., Ltd., 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JapanClinical Planning and Development, Medical HQs, Eisai Co., Ltd., 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JapanTo date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patient population. In a post-marketing observational cohort study, 150 patients previously treated with botulinum toxin type A were enrolled, of whom 138 were followed up for 1 year after the initial type B injection. Final observation data were available for 122 patients. Efficacy was evaluated using the Toronto Western Spasmodic Torticollis Rating Scale. Total score improved from 39.9 at baseline to 34.3 at 4 weeks after the first injection, and pain score improved from 8.9 to 7.9. Improvements were maintained through six further injections in two subpopulations: patients who showed resistance to botulinum toxin type A and patients who were not type A resistant but switched to type B. For a number of patients, even low doses (<5000 units) of botulinum toxin type B demonstrated efficacy. These findings support the efficacy of botulinum toxin type B in clinical settings for the management of CD symptoms, including pain, even at low doses, regardless of the patient's botulinum toxin type A resistance status.http://www.sciencedirect.com/science/article/pii/S2405650221000678Cervical dystoniaPost-marketing observational studyBotulinum toxin type ABotulinum toxin type BToronto Western Spasmodic Torticollis Rating Scale |
| spellingShingle | Ryuji Kaji Akira Endo Michiko Sugawara Mika Ishii Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan eNeurologicalSci Cervical dystonia Post-marketing observational study Botulinum toxin type A Botulinum toxin type B Toronto Western Spasmodic Torticollis Rating Scale |
| title | Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan |
| title_full | Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan |
| title_fullStr | Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan |
| title_full_unstemmed | Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan |
| title_short | Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: A post-marketing observational study in Japan |
| title_sort | efficacy of botulinum toxin type b rimabotulinumtoxinb in patients with cervical dystonia previously treated with botulinum toxin type a a post marketing observational study in japan |
| topic | Cervical dystonia Post-marketing observational study Botulinum toxin type A Botulinum toxin type B Toronto Western Spasmodic Torticollis Rating Scale |
| url | http://www.sciencedirect.com/science/article/pii/S2405650221000678 |
| work_keys_str_mv | AT ryujikaji efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan AT akiraendo efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan AT michikosugawara efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan AT mikaishii efficacyofbotulinumtoxintypebrimabotulinumtoxinbinpatientswithcervicaldystoniapreviouslytreatedwithbotulinumtoxintypeaapostmarketingobservationalstudyinjapan |